Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586071 | 0.82 | ALDH1A1 (0.35) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL7916957 | 0.79 | SMN1; SMN2 (0.58) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL579380 | 0.76 | SMN1; SMN2 (0.55) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL9880035 | 0.76 | SMN1; SMN2 (0.51) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL578878 | 0.76 | SMN1; SMN2 (0.51) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL578877 | 0.76 | SMN1; SMN2 (0.51) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL586613 | 0.75 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL8513847 | 0.75 | ALDH1A1 (0.55) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL17807630 | 0.74 | ALDH1A1 (0.85) | ALDH1A1MEN1KMT2AGAAPKM | |
| SCHEMBL10321569 | 0.74 | SMN1; SMN2 (0.49) | ALDH1A1MEN1KMT2AGAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735414-B2 | Indole derivatives and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2417122-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117932-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184574-A1 | INDOLE DERIVATIVES AND METHODS FOR ANTIVIRAL TREATMENT | IDO1, IRF3, MAVS | ALDH1A1 2672/4885MEN1 4766/4885KMT2A 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.